OTIPRIO® ciprofloxacin otic suspension 6%

OTIVIDEX™

A sustained-exposure formulation of the steroid dexamethasone that is in two Phase 3 clinical trials for patients with Ménière's disease - AVERTS-1 in the U.S. and AVERTS-2 in Europe...
LEARN MORE »

OTO-311

A sustained-exposure formulation of the NMDA receptor antagonist gacyclidine for the treatment of tinnitus that will be evaluated in a Phase 2 clinical trial that is expected to start in the second half of 2017...
LEARN MORE »

OTO-4XX

Otonomy has acquired the rights to multiple product candidates for our fourth development program, which will target age-related hearing loss, also known as presbycusis....
LEARN MORE »